日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH)

控制末端补体活性和血管内溶血在阵发性睡眠性血红蛋白尿症(PNH)中的重要性

Hill, Anita; Hotermans, Christophe; Pirozzi, Gianluca

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

STRIVE研究预设的2年中期分析:复发缓解型多发性硬化症诊断后3年内接受那他珠单抗治疗的疗效

Perumal, Jai; Fox, Robert J; Balabanov, Roumen; Balcer, Laura J; Galetta, Steven; Makh, Shavy; Santra, Sourav; Hotermans, Christophe; Lee, Lily

Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

采用NeuroTrax评估的接受那他珠单抗治疗的复发型多发性硬化症患者认知功能改善情况:一项为期2年的回顾性分析

Gudesblatt, Mark; Wissemann, Karl; Zarif, Myassar; Bumstead, Barbara; Fafard, Lori; Wilken, Jeffrey; Blitz, Karen; Buhse, Marijean; Santra, Sourav; Hotermans, Christophe; Lee, Lily

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

更正:纳他珠单抗治疗复发型多发性硬化症患者认知功能改善情况(NeuroTrax评估):一项为期2年的回顾性分析

Gudesblatt, Mark; Wissemann, Karl; Zarif, Myassar; Bumstead, Barbara; Fafard, Lori; Wilken, Jeffrey; Blitz, Karen; Buhse, Marijean; Santra, Sourav; Hotermans, Christophe; Lee, Lily

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

纳他珠单抗可改善复发缓解型多发性硬化症患者的步行能力:前瞻性 TIMER 研究的结果和 AFFIRM 研究的回顾性分析

Voloshyna, N; Havrdová, E; Hutchinson, M; Nehrych, T; You, X; Belachew, S; Hotermans, C; Paes, D

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis

缓释型富马酸二甲酯治疗多发性硬化症的临床和神经放射学效应的时间进程

Kappos, L; Giovannoni, G; Gold, R; Phillips, J T; Arnold, D L; Hotermans, C; Zhang, A; Viglietta, V; Fox, R J